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LETTER TO THE EDITOR
Quality of Life in Hemophilia Complicated by  
Inhibitors 
 
 
Dear Editor, 
Inhibitors in patients with hemophilia are a rare com-
plication which leads to pain, disability and impair-
ment in quality of life. Recent advances in treatment 
have improved this situation, doubtful of whether it 
improves patients` quality of life or not.
1  
The overall prevalence of inhibitors in patients 
with hemophilia A or B in Iran is estimated to be ap-
proximately 9% and 3% respectively; patients  with 
moderately severe (factor levels 1-5%) and severe 
hemophilia A (<1%) have a greater risk of developing  
inhibitors, with reported the prevalence between 7% 
and 20%.
2-4 The introduction and availability of by-
passing products in treatment have definitively con-
tributed to prolong patients` life expectancy and to 
improve their quality of life.
5 The management of 
hemophiliacs with inhibitors is particularly expensive 
in comparison with the treatment of hemophiliacs 
without inhibitors. The aim of this study was to eval-
uate the quality of life in severe hemophilia patients 
with inhibitor compared with quality of life of 52 
non-inhibitor severe hemophilia patients. 
This cross-sectional study was carried out in Shiraz 
Hemophilia Center, a major referral center in south of 
Iran. To reach the objectives of the study, the short form 
36 questionnaire was applied. The informed consent 
was obtained before the study. Six severe hemophilia A 
patients with the age range of 11-32 years old, (<1% 
arriving) and high responders, high titer (>5 Bethesda 
uni) were selected. SF-36 was provided for patients ret-
rospectively. The control group consisted of 52   
non-inhibitor severe hemophilia A patients. To evaluate 
quality of life, both groups were interviewed by struc-
tured questionnaire SF-36. 
The SF-306 questionnaire is considered as a 
standard instrument for patient-based health care out-
come assessment.
6,7 It has been recently validated in 
Iran, and has been used in several studies ranging 
from epidemiological to clinical trials. Applicable to 
adults and adolescents, SF-36 assesses eight dimen-
sions of Health related quality of life (HRQOL) 
which is related to the physical and mental compo-
nents of health perception: physical functioning, role- 
physical and bodily pain were more related to the 
physical component; social functioning, role, emo-
tional and mental health were more related to the 
mental component; finally, energy/vitality and gen-
eral health relate to both components. These 8 dimen-
sions can be classified in two summary scores (physi-
cal component summary (PCS) and the mental com-
ponent summery (MCS)).
8,9 To test the internal con-
sistency of SF-36 in inhibitor patients, the Cronbach`s 
alpha was computed, with values greater than 0.70 
considered satisfactory.
8 Descriptive statistics was 
also applied to describe HRQOL and health status 
measurement variables. Data were analyzed using 
Mann Whitney test. 
The main demographic and clinical characteristics 
were shown in Table 1. Fifty percent of cases and 
33% of controls had hepatitis C virus positive and 
83% of cases and 33% of controls had a high degree 
of disability due to hemophilia. On average, the level 
Table 1: Demographic and clinical characteristics of severe hemophiliacs with  and without inhibitor. 
Variables  Value for inhibitors Value for non-inhibitors
Age (year) 
Mean (+SD) 
Median (min-max) 
25.5 
17.5 
(11-32) 
25.6 
27.5 
(10-33) 
Weight (kg) 
Mean (+SD) 
Median (min-max) 
69 
67.5 
(35-90) 
66 
69 
(38-80) 
Frequency of: 
HIV infection (%) 
HBV infection (%) 
HCV infection (%) 
 
0 
0 
50 
 
0 
0 
33.3 
Disability: 
Patients with hemophilia-related disability (%) 
 
83.3 
 
33.3 
Orthopedic functioning: 
Patients with choronic disability (%) 
 
85.5 
 
66.6 
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of HRQOL shown by the sample of subjects was   
stable over time (data not shown). Our results showed 
that SF-36 gave lower scores in the dimensions more 
related to the physical components of health (physical 
functioning, role- physical and bodily pain) and high-
er scores in dimensions more related to the mental 
components (social functioning, role-emotional, men-
tal health) both for inhibitors and non-inhibitors but 
scores in dimensions related to physical components 
in inhibitors are lower than in non-inhibitors (p-
value=0.04) and the scores for physical dimensions 
showed more differences compared with this score 
for non-inhibitors. For dimensions equally related to 
both physical and mental health components, the gen-
eral health score was relatively low, while the vitality 
score was higher. The global physical and mental 
measures mean scored were 36.9 and 50.2 respective-
ly. Internal consistency of SF-36 was excellent, with 
Cronbach`s alpha values ranging from 0.8 to 0.9 for 
every dimensions of the questionnaire. 
It appears that the expensive care of inhibitor patients 
led to an unsatisfactory level of HRQOL both in inhibi-
tors and non-inhibitors and showed an important im-
pairment of physical health perception and the mental 
domains, excluding social activities, did not show sub-
stantial differences. Substantial difference was found 
between inhibitors and non-inhibitors
10 with regard to 
domains more related to the physical and mental com-
ponents of health perception. Non-inhibitors had slightly 
higher values for vitality compare with inhibitors and 
higher for general health. Moreover, mental health per-
ception, as summarized by the MCS score, was similar 
between these two groups. While the PCS score, per-
taining to the physical component of health perception 
was higher in non-inhibitor patients. 
Our results showed that the type of treatment 
used for inhibitors was not that much effective and 
these patients needed more care for physical status. 
Also this situation is similar for non-inhibitor pa-
tients. For those inhibitors by HCV or HBV, the re-
lated scores for physical dimension is less than the 
scores of those without HCV and HBV. The limita-
tion of the study was small sample size and further 
study with larger sample size is suggested. In con-
clusion, inhibitor patients need more caring regard-
ing optimal management. 
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